No Detail Found!

Screening for Early Biomarkers of Cisplatin-Induced Acute Kidney Injury in Rats Through Serum Metabolomics Technology

Author(s)
Jinru Yang The First Clinical Medical College of Pharmacy, Lanzhou University,Gansu,China
Mingkang Zhang The Pharmacy of Lanzhou University,Gansu,China
Fenglin Ran The Pharmacy of Lanzhou University,Gansu,China
Xueyan Gou The First Clinical Medical College of Pharmacy, Lanzhou University,Gansu,China
Yanrong Ma Department of Pharmacy, The First Hospital of Lanzhou University,Gansu,China
Xinan Wu The First Clinical Medical College of Pharmacy, Lanzhou University, Gansu, China; Department of Pharmacy, The First Hospital of Lanzhou University, Gansu, China
Abstract
Objective: To systematically identify early biomarkers of cisplatin-induced acute kidney injury (AKI) in rats. Study Design: An experimental study. Place and Duration of the Study: Experimental Animal Laboratory of Lanzhou University, Gansu, China, and the Department of Pharmacy, The First Hospital of Lanzhou University, Gansu, China, from July 2022 to October 2023. Methodology: In this study, an AKI model was established by continuously injecting cisplatin into rats at a dose of 1 mg/kg once a day for control group and for 2, 3, 4, and 5 days to other four groups, respectively. Subsequently, rat plasma samples were collected for metabolomics analysis to identify early di erentiated metabolites in the plasma prior to creatinine elevation. Furthermore, accurate HPLC-MS/MS methods were developed to validate the biomarker variation in other AKI models. Results: The occurrence of time-dependent renal cortical injury and signi cant alteratio nfscreatinine (Cr) concentration were observed on day-4 and 5, which demonstrated successful model construction. Sixty-sixcompounds changed on Day-2 while 61 compounds changed on Day-3. Eleven compounds with variable importance in projection (VIP) >1.5 and false discover rate (FDR) <0.2 were selected and identi ed by HPLC-MS/MS. Among these, N-acetylglutamine and citramalic acid changed earlier than serum creatinine (sCr) in the AKI model. Conclusion: N-acetylglutamine and citramalic acid may serve as early biomarker of cisplatin-induced AKI.
Publication Details
Page(s) 936-941
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 8, Year: 2024

Request the full text from PASTIC

Keywords
LC-MS/MS, Acute Kidney Injury, Biomarker, Rats, Cisplatin, Metabolomics
0

Citations

0

Downloads

72

Views